Search clinical trials for: SCY-078

Total 2745 results

Scynexis, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment (FURI)

Coccidioidomycosis | Invasive Pulmonary Aspergillosis | Allergic Bronchopulmonary Aspergillosis | Histoplasmosis | Chronic Pulmonary Aspergillosis | Blastomycosis | Invasive Candidiasis | Recurrent Vulvovaginal Candidiasis | Mucocutaneous Candidiasis | Other Emerging Fungi

United States, Spain, United Kingdom, Austria, Pakistan, Germany, Netherlands, South Africa
Scynexis, Inc.

Completed

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES) (CARES)

Candidemia | Candidiasis, Invasive

Pakistan, India, United States, South Africa
Scynexis, Inc.

Completed

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (VANISH 303)

Candida Vulvovaginitis

United States
Scynexis, Inc.

Completed

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (Vanish 306)

Candida Vulvovaginitis

United States, Bulgaria
Scynexis, Inc.
Inncelerex

Completed

ADME Study of [14C]-Ibrexafungerp in Healthy Male Subjects

Fungal Infection

United Kingdom
Sun Pharma Advanced Research Company Limited

Completed

Study of Doxorubicin in Patients With Metastatic Breast Cancer/Advanced Ovarian Cancer

Breast Cancer and Ovarian Cancer
Scynexis, Inc.
Clinical Network Services (CNS) Pty Ltd

Completed

Study to Evaluate the Effect of SCY-078 on the PK of Dabigatran in Healthy Subjects

Pharmacokinetics

Australia
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

China
Scynexis, Inc.
Clinical Network Services (CNS) Pty Ltd

Completed

Study to Evaluate the Effect of SCY-078 (Ibrexafungerp) on the PK of Pravastatin in Healthy Subjects

Pharmacokinetics

Australia
Suzhou Yabao Pharmaceutical R&D Co., Ltd.

Completed

Single Ascending Oral Doses of SY-008 in Healthy Subjects

Diabetes

China
Scynexis, Inc.

Completed

Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)

Invasive Pulmonary Aspergillosis

United States, Belgium, Canada, Germany, South Africa
Peking Union Medical College Hospital

Completed

177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
SciClone Pharmaceuticals

Unknown

Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer

Oral Mucositis

United States
SciClone Pharmaceuticals

Completed

Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer (SCV-07 OM)

Head and Neck Cancer | Oral Mucositis

United States
Takeda
Takeda Development Center Americas, Inc.

Terminated

A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery

Crohn Disease

United States, Germany, Austria, France, United Kingdom
Takeda

Completed

A Study of TAK-079 in People With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Spain, Canada, Serbia, Italy, Poland
SciClone Pharmaceuticals

Completed

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

Chronic Hepatitis C

United States
SciClone Pharmaceuticals

Completed

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

Chronic Hepatitis C

United States
Millennium Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus | Lupus Erythematosus, Systemic

United States
Evolva SA

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EV-077 in Type 2 Diabetic Subjects

Type 2 Diabetes

Germany
University of Pisa

Recruiting

Clinical Outcomes of Immediate Implants With or Without a Volume-stable Collagen Matrix

Edentulous Alveolar Ridge

Italy
Travere Therapeutics, Inc.

Recruiting

A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment (HARMONY)

Homocystinuria

United States
Taejoon Pharmaceutical Co., Ltd.

Completed

A Prospective, Randomized, Single-blinded (Evaluator), Parallel, Multi-center, Phase 3 Trial in Bowel Preparation for Colonoscopy

Bowel Preparation

Korea, Republic of
Reiley Pharmaceuticals Inc.

Unknown

[Tc-99m]-RPI-087 as an Imaging Marker in Osteoarthritis of the Knee Compared to Healthy Volunteers

Healthy | Osteo Arthritis Knee

Canada
Dipexium Pharmaceuticals, Inc.

Completed

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (OneStep-1)

Diabetic Foot Infection

United States
GlaxoSmithKline

Completed

Non-Inferiority of Various GSK Bio's Influenza Vaccine Presentations in Adults Aged 65 Years and Over

Influenza

Norway, Estonia, Denmark
Valbiotis

Recruiting

Effect of the Food Supplement TOTUM-070 on Lipid Metabolism (HEARTII)

Hypercholesterolemia

Germany
NovaRock Biotherapeutics, Ltd

Recruiting

A Study of NBL-028 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Fochon Pharmaceuticals, Ltd.

Recruiting

Study of FCN-098 in Patients With Advanced Solid Tumor

Solid Tumor

China
Valbiotis
University Hospital, Clermont-Ferrand

Terminated

Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk (OLALIP)

Atherosclerosis | Dyslipidemias | Hypercholesterolemia | Cardiovascular Risk Factor | Cardio-metabolic Risk

France
Antengene Therapeutics Limited

Terminated

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Hepatocellular Carcinoma

Korea, Republic of, Taiwan, China
NS Pharma, Inc.

Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Exicure, Inc.

Completed

A Study of AST-008 in Healthy Subjects

Healthy Volunteer Study

United Kingdom
Cascadian Therapeutics Inc.

Completed

Phase I Trial of PX-478

Lymphoma | Advanced Solid Tumors

United States
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
National Center for Complementary and Integrative...

Withdrawn

Preliminary Human Trial of NPI-028

Alcoholism
IDEA AG

Completed

Effect of IDEA-070 on Pain and Inflammation Induced by PDT

Actinic Keratosis

Germany
Shijiazhuang Yiling Pharmaceutical Co. Ltd

Recruiting

A Study of Bio-008 in Subjects With Advanced or Metastatic Solid Tumours

Solid Tumor, Adult

China
Shenzhen TargetRx, Inc.
Peking University People's Hospital

Recruiting

TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients

Chronic Myelogenous Leukemia

China
Antengene Discovery Limited

Recruiting

A Study of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies (ATRIUM)

Advanced Solid Tumors | Hematological Malignancies

Australia
Pfizer
Emergent Product Development Seattle LLC

Completed

Study Evaluating Single Doses Of SBI-087 in Subjects With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada
AbbVie (prior sponsor, Abbott)

Completed

A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Hepatitis C Virus Infection

United States
Takeda

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple-Dose TAK-058 in Healthy Participants

Healthy Volunteers

United States
Chong Kun Dang Pharmaceutical

Completed

A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378

Type II Diabetes

Korea, Republic of
Dipexium Pharmaceuticals, Inc.

Completed

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers (OneStep-2)

Diabetic Foot Infection

United States
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
Takeda

Completed

A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants

Autoimmune Disease

United Kingdom
Scynexis, Inc.

Completed

Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients

Chronic Hepatitis C

United States
Shenzhen TargetRx, Inc.
M.D. Anderson Cancer Center

Not yet recruiting

TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Cullinan Oncology Inc.

Recruiting

A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

NHL | NHL, Relapsed, Adult

United States

3

Subscribe